These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30010839)

  • 61. Soluble levels and endogenous vascular gene expression of
    Martín-Núñez E; Donate-Correa J; López-Castillo Á; Delgado-Molinos A; Ferri C; Rodríguez-Ramos S; Cerro P; Pérez-Delgado N; Castro V; Hernández-Carballo C; Mora-Fernández C; Navarro-González JF
    Clin Sci (Lond); 2017 Nov; 131(21):2601-2609. PubMed ID: 28963437
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
    Arida A; Protogerou AD; Konstantonis G; Fragiadaki K; Kitas GD; Sfikakis PP
    Rheumatology (Oxford); 2017 Jun; 56(6):934-939. PubMed ID: 28160488
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis.
    Aghili N; Devaney JM; Alderman LO; Zukowska Z; Epstein SE; Burnett MS
    Neuropeptides; 2012 Dec; 46(6):367-71. PubMed ID: 23122333
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis.
    Gunawan A; Fajar JK; Tamara F; Mahendra AI; Ilmawan M; Purnamasari Y; Kartini DA; Winoto ES; Saifillah ES; Wulandari DS; Krisna PA; Mayasari ED; Dantara TWI; Wicaksono RS; Soeatmadji DW
    F1000Res; 2020; 9():252. PubMed ID: 34035901
    [No Abstract]   [Full Text] [Related]  

  • 67. Impact of chronic kidney disease stages on atherosclerotic plaque components on optical coherence tomography in patients with coronary artery disease.
    Sugiyama T; Kimura S; Ohtani H; Yamakami Y; Kojima K; Sagawa Y; Hishikari K; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Cardiovasc Interv Ther; 2017 Jul; 32(3):216-224. PubMed ID: 27339299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study.
    Kashiyama K; Sonoda S; Muraoka Y; Suzuki Y; Kamezaki F; Tsuda Y; Araki M; Tamura M; Takeuchi M; Abe H; Okazaki M; Fujino Y; Otsuji Y
    Int J Cardiovasc Imaging; 2015 Jun; 31(5):935-45. PubMed ID: 25724567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Accelerated atheromatosis and arteriosclerosis in primary systemic vasculitides: current evidence and future perspectives.
    Argyropoulou OD; Protogerou AD; Sfikakis PP
    Curr Opin Rheumatol; 2018 Jan; 30(1):36-43. PubMed ID: 29040156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nonculprit coronary plaque characteristics of chronic kidney disease.
    Kato K; Yonetsu T; Jia H; Abtahian F; Vergallo R; Hu S; Tian J; Kim SJ; Lee H; McNulty I; Lee S; Uemura S; Jang Y; Park SJ; Mizuno K; Yu B; Jang IK
    Circ Cardiovasc Imaging; 2013 May; 6(3):448-56. PubMed ID: 23536265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Perpiñan H; Amigo N; Castro E; Alonso N; Mauricio D; Fernandez E; Valdivielso JM
    Clin Kidney J; 2021 Dec; 14(12):2591-2599. PubMed ID: 34950470
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Atheromatosis extent in coronary artery disease is not correlated with apolipoprotein-E polymorphism and its plasma levels, but associated with cognitive decline.
    Lima LM; Carvalho Md; Ferreira CN; Fernandes AP; Neto CP; Garcia JC; Reis HJ; Janka Z; Palotás A; Sousa Md
    Curr Alzheimer Res; 2010 Sep; 7(6):556-63. PubMed ID: 20455863
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The association of Klotho polymorphism with disease progression and mortality in IgA nephropathy.
    Ko GJ; Lee EA; Jeon US; Pyo HJ; Chin HJ; Chae DW; Kim S; Kwon YJ
    Kidney Blood Press Res; 2012; 36(1):191-9. PubMed ID: 23147162
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Upstream and downstream regulators of Klotho expression in chronic kidney disease.
    Li SS; Sheng MJ; Sun ZY; Liang Y; Yu LX; Liu QF
    Metabolism; 2023 May; 142():155530. PubMed ID: 36868370
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment.
    Coll B; Betriu A; Martínez-Alonso M; Borràs M; Craver L; Amoedo ML; Marco MP; Sarró F; Junyent M; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2010 Sep; 25(9):3017-25. PubMed ID: 20237061
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Coban M; Inci A; Yılmaz U; Asilturk E
    Kidney Blood Press Res; 2018; 43(4):1160-1173. PubMed ID: 30064143
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aquaporin 11 rs2276415 variant and progression of chronic kidney disease.
    Han B; Wu X; Huang PP; Zhu FX; Liu S
    Nephrol Dial Transplant; 2019 Jun; 34(6):970-973. PubMed ID: 30010847
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Influence of exogenous growth hormone administration on circulating concentrations of α-klotho in healthy and chronic kidney disease subjects: a prospective, single-center open case-control pilot study.
    Adema AY; de Roij van Zuijdewijn CLM; Hoenderop JG; de Borst MH; Ter Wee PM; Heijboer AC; Vervloet MG;
    BMC Nephrol; 2018 Nov; 19(1):327. PubMed ID: 30442108
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Klotho/FGF23 Axis in CKD.
    Tsuchiya K; Nagano N; Nitta K
    Contrib Nephrol; 2015; 185():56-65. PubMed ID: 26023015
    [TBL] [Abstract][Full Text] [Related]  

  • 80. B- and T-lymphocyte attenuator could be a new player in accelerated atherosclerosis associated with chronic kidney disease.
    Dolade N; Rayego-Mateos S; Garcia-Carrasco A; Guerin M; Martín-Ventura JL; Ruiz-Ortega M; Tharaux PL; Valdivielso JM
    Clin Sci (Lond); 2023 Sep; 137(17):1409-1429. PubMed ID: 37655751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.